At 42.7x trailing earnings and 20x forward earnings, the market is clearly discounting a rebound, but not pricing in hypergrowth. A PEG of 1.5 suggests growth is not cheap, yet not egregiously overpriced either. The real tension is balance-sheet risk: an Altman Z-Score of 2.2 puts the company in the grey zone, not distressed but hardly fortress-like, while a Debt/Equity ratio of 9.20% and a Current Ratio of 2.1 indicate manageable leverage and solid liquidity. This is not a deep value cigar butt, but at a $2,265M market cap with improving forward expectations, it looks like a cautious turnaround priced for moderate execution rather than breakout expansion.